Most severely ill patients initially have single organ failure (ie, respiratory failure) but some progress to systemic disease with multiple organ dysfunction.
En la prevención todos jugamos un papel importante
comparta este artículo en sus redes sociales
The new Coronavirus infection (classified as COVID-19), first identified in December 2019 in Wuhan, China, has contributed to significant mortality in several countries, with the number of infected cases increasing exponentially across the world. Most severely ill patients initially have single organ failure (ie, respiratory failure) but some progress to systemic disease with multiple organ dysfunction. One of the most important poor prognostic characteristics in these patients is the development of coagulopathies.
Similarly, Huang and his colleagues showed that the level of D-DIME on admission was higher in patients who needed critical care support (mean level of D-DIMER 2.4MG / L) than those patients who did not require it (mean level DIMERO-D 0.5 mg / L). For these reasons, patients who have markedly elevated D-DIMER values (which can be arbitrarily defined as a three- or four-fold increase) should be considered for hospital admission even in the absence of other serious symptoms, as this means clearly increased thrombin generation.
In patients who develop sepsis due to various infectious agents, the development of coagulopathy is one of the key and persistent characteristics that is associated with a poor prognosis.
“One of the most common laboratory findings seen in COVID-19 patients requiring hospitalization has been an increase in DIMERO-D. In a study specifically looking at abnormal coagulation parameters, Tang and colleagues have identified markedly elevated D-DIMERS as one of the predictive parameters for mortality. They noted an average value of DIMER-D of 2.12 µg / ml in non-survivors while it was 0.61 µg / ml in survivors, the normal laboratory ranges being <0.50 µg / ml "